Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Stopped Primary endpoint of parent study AC-055-305/MAESTRO (NCT01743001) not met.

Conditions

• Pulmonary Arterial Hypertension

Interventions

• DRUG: Macitentan 10 mg tablet, once daily.

Sponsor

Actelion